InMed Pharmaceuticals Inc. (INM) Institutional Ownership

Ownership Summary

InMed Pharmaceuticals Inc. (NASDAQ:INM) showed up in the 13F filings of 7 institutional investors as of December 2025.

• These investors held 5.7% of outstanding shares in December 2025, down from 7.7% in September 2025.
• They increased total shares held in INM by 3.06% quarter over quarter, and investors in InMed Pharmaceuticals increased 16.67% from a year ago.
• Of these 7 holders, 3 added to their stakes in InMed Pharmaceuticals, 1 trimmed positions, and 3 made no changes.
• Altogether, these fund groups held 227.05K shares in INM by December 2025, up by 6.74K shares quarter on quarter, and up 178.15K shares year over year.
• SABBY MANAGEMENT, LLC holds the largest position in INM at 220.26K shares as of December 31, 2025, or 5.57% of shares outstanding.
• Top purchasers of INM stock for the quarter ending December 2025 included CITADEL ADVISORS LLC (46.97K), Virtu Financial LLC (19.98K), TWO SIGMA SECURITIES, LLC (18.72K), SABBY MANAGEMENT, LLC (18.63K), UBS Group AG (7.69K).
• Per Business Quant, the top 9 investors in INM for the quarter ending December 2025 include SABBY MANAGEMENT, LLC (220.26K), CITADEL ADVISORS LLC (46.97K), Virtu Financial LLC (19.98K), TWO SIGMA SECURITIES, LLC (18.72K), UBS Group AG (8.07K), Private Wealth Management Group, LLC (5.0K), SBI Securities Co., Ltd. (300), Banque Cantonale Vaudoise (6), Federation des caisses Desjardins du Quebec (1).